Welcome to Legit.Health's Data Room
This space gathers the operational, financial, and regulatory documentation Legit.Health makes available to potential investors during due diligence. All sections are versioned and updated regularly.
The proposition
Legit.Health is a clinical AI platform with €401K ARR (June 2026) within a hybrid revenue model that generated €604K recognised revenue (+49%) and €848K in billings (+145%) during 2025.
Currently raising a bridge round of €2M to take ARR from €401K to €1M, the milestone that opens the Series A at materially improved terms.
The platform has processed 256K+ clinical reports to date, with monthly volume up ~10x since the Seed round, and won the Startup World Cup regional final (June 2026).
Key metrics 2025
ARR vs. the full picture
ARR captures only the recurring hospital/insurance layer (66% of 2025 revenue). The full business signed €903K in contract value across 16 deals in 2025: J&J (Psoriasis Phase 3), Boehringer Ingelheim, Sagimet/ICON (Alopecia Phase 3), SESPA, Sanitas/BUPA. Full revenue model →
Company snapshot
Bridge Round in progress
A €2M bridge to reach €1M ARR is in process, built for maximum capital efficiency: only €750K is dilutive (a convertible note anchored by existing investors, with Mutua Ventures pro-rata confirmed). On top sit €600K of loans in arrangement (ICO Crecimiento, Elkargi) and €1.5M of grants requested and in evaluation (non-dilutive, subject to approval, resolutions from September 2026). Convertible plus loans (€1.35M, only €750K dilutive) reach €1M ARR on their own; grants complete the €2M and, if more is awarded, take the blended raise higher as non-dilutive upside. The convertible converts into the Series A (terms in the term sheet, under NDA).
Bridge use of funds: ~45% commercial expansion (BUPA Europe, pharma frames, customer success) · ~25% FDA + US regulatory · ~20% runway buffer to Q2 2027 · ~10% operations.
Series A planned post-bridge: targeted H2 2026 / H1 2027 (terms in the term sheet, under NDA), once Bridge milestones (€1M ARR, FDA pre-sub, 2+ pharma frames) are hit.